Finasteride and sperm concentration: Rapid systematic review
DOI:
https://doi.org/10.66344/jpad.v30i3.1464Keywords:
Finasteride, Sperm, Concentration, Fertility, Sexual, Spermatogenesis.Abstract
Background Finasteride is approved treatment for androgenic alopecia and benign prostatic hypertrophy. It may have an effect on sperm, however the data is lacking. Few published papers described the association between 1mg/day of finasteride treatment for androgenic alopecia and sperm.
Objective Reviewing all articles describing the association between treatment of finasteride (1mg/day) for androgenic alopecia and sperm concentration.
Methods Comprehensive literature review using PubMed as a search engine from 1980 till present. Main outcome measures: Sperm concentrations during treatment and after treatment are the main outcome measures of this analysis.
Results Seven papers were found on PubMed using the mentioned keywords on the management of androgenic alopecia giving a total of 113 subjects in all papers. No baseline sperm concentration was measured except for one paper. All papers but one (n=22) showed increase in sperm concentration after cessation of finasteride. However, the largest study (n=91) had baseline, during and post treatment measurements of sperm and showed no change in sperm concentration level.
Conclusion The analysis of reviewed papers showed that long-term treatment with finasteride is safe on sperm concentration. However, there are some signs of short-term effect during treatment.
References
Varothai S, Bergfeld WF. Androgenetic Alopecia: An Evidence-Based Treatment Update. Am J Clin Dermatol. 2014;15(3):217-30.
Wang TL, Zhou C, Shen YW, Wang XY, Ding XL, Tian S. Prevalence of androgenetic alopecia in China: A community-based study in six cities. Br J Dermatol. 2010;162(4):843-7.
Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747-53.
Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, Walker SE, Haberer LJ, Clark RV. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659-65.
Overstreet, J. W., Fuh, V. L., Gould, J., Howards, S. S., Lieber, M. M., Hellstrom, W., Shapiro, S., Carroll, P., Corfman, R. S., Petrou, S. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 1999;162(4):1295-300.
Collodel G, Scapigliati G, Moretti E. Spermatozoa and chronic treatment with finasteride: a TEM and FISH study. Arch Androl. 2007;53(4):229-33.
Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril. 2008;90(3):849.e17-9.
Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril. 2011;95(5):1786.e9-11.
Ricci G, Martinelli M, Luppi S, Lo Bello L, De Santis M, Skerk K, Zito G. Finasteride and fertility: case report and review of the literature. J Drugs Dermatol. 2012;11(12):1511-3.
Şalvarci A, Istanbulluoğlu O. Secondary infertility due to use of low-dose finasteride. Int Urol Nephrol. 2013;45(1):83-5.
Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013 ;100(6):1542-6.
Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT, Vogelsong KM. World Health Organization reference values for human semen characteristics. Hum Reprod Update.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Abdulmajeed M Alajlan, Suliman Alfaraj
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
